[PRNewswire] Novavax to Participate in Fireside Chat at Devex @ UNGA 76
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
(GAITHERSBURG, Md., Sept. 20, 2021 PRNewswire=연합뉴스) Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer, will be interviewed at Devex @ UNGA 76 on September 21 at 8:50 a.m. The event is hosted by the media outlet Devex and is taking place September 21-23 via livestream as part of its coverage of the 76th meeting of the United Nations General Assembly (UNGA 76). Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion along with fostering global vaccine access.
Interview details are as follows:
Date: Tuesday, September 21, 2021
Time: 8:50 - 9:05 a.m.
Location: Livestream [https://pages.devex.com/devex-at-unga-76.html ]
Title: Fireside chat: A status report on the COVID-19 vaccine rollout
Novavax panelist: John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer
Moderator: Jenny Lei Ravelo, Senior Reporter, Devex
For more information or to register for the fireside chat, visit:
https://pages.devex.com/devex-at-unga-76.html
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter [https://twitter.com/novavax ] and LinkedIn [https://www.linkedin.com/company/novavax ].
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com
Media
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
media@novavax.com
Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg
Novavax Logo
Source: Novavax, Inc.
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
저작권자(c)연합뉴스. 무단전재-재배포금지
- 튀르키예·시리아 지진 사망자 하루만에 5천명 넘어서
- 튀르키예에 韓긴급구호대 110명 급파…단일 파견으로 최대규모
- 법원, '베트남전 민간인 학살' 韓정부 배상책임 첫 인정
- 김기현에 힘실은 나경원…尹대통령·친윤과 '정치적 절연' 부담?
- 대정부질문 이틀째…여야, 난방비 폭탄 '네탓 공방'
- 이태원참사 유족 "서울시와 소통 중단…분향소 지킬것"
- 질병청장 "중국 비자제한 조기해제검토…코로나 정기접종추진"
- 尹 "민첩·유연한 정부…민간 인사시스템·파격 성과주의 도입"
- 이재명, 10일 2차 검찰 출석…최고위 이후 오전 11시 예상
- 주목받는 김성태 '금고지기'의 입…태국서 추방, 금주 입국 전망